Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients

Journal of Thoracic Oncology

Volumn 5, Issue 10, 2010, Pages 1536-1543

  Al Saad, Samer ^a,b   Al Shibli, Khalid ^a,c   Donnem, Tom ^a,b   Andersen, Sigve ^a,b   Bremnes, Roy M ^a,b   Busund, Lill Tove ^a,b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c NORDLAND HOSPITAL   (Norway)

Author keywords

Erb family members; HER2; NSCLC; Prognosis; SISH; Tissue microarray

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 17; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE DOSAGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SEX DIFFERENCE; UNIVARIATE ANALYSIS;

EID: 77958161521     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181ea510a     Document Type: Article

References (51)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Timotheadou E, Skarlos DV, Samantas E, et al. Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patients. Anticancer Res 2007;27:4481-4489.
3. Varella-Garcia M, Mitsudomi T, Yatabe Y, et al. EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort. J Thorac Oncol 2009;4:318-325.
4. Xu JM, Han Y, Duan HQ, et al. EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib. J Cancer Res Clin Oncol 2009;135:771-782.
5. Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000; 19:3159-3167.
6. Suo Z, Nesland JM. Type 1 protein tyrosine kinases in breast carcinoma: a review. Ultrastruct Pathol 2002;26:125-135. (Pubitemid 34625947)
7. Prenzel N, Fischer OM, Streit S, et al. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 2001;8:11-31. (Pubitemid 32520251)
8. Hobbs SS, Coffing SL, Le AT, et al. Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activation. Oncogene 2002;21:8442-8452.
9. Tzahar E, Yarden Y. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochim Biophys Acta 1998;1377:M25-M37. (Pubitemid 28144426)
10. Pinkas-Kramarski R, Soussan L, Waterman H, et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996;15:2452-2467. (Pubitemid 26151185)
11. Alimandi M, Romano A, Curia MC, et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 1995;10:1813-1821.
12. Koumakpayi IH, Diallo JS, Le Page C, et al. Expression and nuclear localization of ErbB3 in prostate cancer. Clin Cancer Res 2006;12: 2730-2737. (Pubitemid 43752110)
13. Grivas PD, Antonacopoulou A, Tzelepi V, et al. HER-3 in colorectal tumourigenesis: from mRNA levels through protein status to clinicopathologic relationships. Eur J Cancer 2007;43:2602-2611. (Pubitemid 350103546)
14. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-8923. (Pubitemid 39665498)
15. Takano T, Fukui T, Ohe Y, et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol 2008;26:5589-5595.
16. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139. (Pubitemid 38637993)
17. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304: 1497-1500. (Pubitemid 38720929)
18. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in nonsmall-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005; 23:857-865. (Pubitemid 46224186)
19. Mountain CF. The international system for staging lung cancer. Semin Surg Oncol 2000;18:106-115. (Pubitemid 30090451)
20. William D. Travis World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press, 2004.
21. Al Saad S, Al-Shibli K, Donnem T, et al. The prognostic impact of NF-kappaB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer. Br J Cancer 2008;99:1476-1483.
22. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18-43. (Pubitemid 46174133)
23. Donnem T, Al-Saad S, Al-Shibli K, et al. Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Clin Cancer Res 2007;13:6649-6657. (Pubitemid 350206800)
24. Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. Clin Cancer Res 2001;7:1850-1855. (Pubitemid 32994816)
25. Korrapati V, Gaffney M, Larsson LG, et al. Effect of HER2/neu expression on survival in non-small-cell lung cancer. Clin Lung Cancer 2001;2:216-219.
26. Szelachowska J, Jelen M, Kornafel J. Prognostic significance of intracellular laminin and Her2/neu overexpression in non-small cell lung cancer. Anticancer Res 2006;26:3871-3876. (Pubitemid 44701474)
27. Meert AP, Martin B, Paesmans M, et al. The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br J Cancer 2003;89:959-965. (Pubitemid 37239194)
28. Nakamura H, Kawasaki N, Taguchi M, et al. Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysis. Cancer 2003;103:1865-1873. (Pubitemid 40563259)
29. Stinchcombe TE, Socinski MA. Current treatments for advanced stage non-small cell lung cancer. Proc Am Thorac Soc 2009;6:233-241.
30. Kancha RK, von Bubnoff N, Peschel C, et al. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. Clin Cancer Res 2009;15:460-467.
31. Agus DB, Bunn PA Jr, Franklin W, et al. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol 2000;27:53-63. (Pubitemid 32172257)
32. Fijolek J, Wiatr E, Rowińska-Zakrzewska E, et al. p53 and HER2/neu expression in relation to chemotherapy response in patients with nonsmall cell lung cancer. Int J Biol Markers 2006:21:81-87. (Pubitemid 44210036)
33. Rosell R. Toward customized trastuzumab in HER-2/neu-overexpressing non-small-cell lung cancers. J Clin Oncol 2004;22:1171-1173. (Pubitemid 41079826)
34. Hirsch FR, Varella-Garcia M, Franklin WA, et al. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer 2002;86:1449-1456. (Pubitemid 34548069)
35. Koutsopoulos AV, Mavroudis D, Dambaki KI, et al. Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: correlation with clinical outcome. Lung Cancer 2007;57:193-200. (Pubitemid 47043186)
36. Cox G, Jones JL, Andi A, et al. A biological staging model for operable non-small cell lung cancer. Thorax 2001;56:561-566. (Pubitemid 32588536)
37. Langer CJ, Stephenson P, Thor A, et al. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J Clin Oncol 2004;22:1180-1187. (Pubitemid 41079829)
38. Gatzemeier U, Groth G, Butts C, et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 2004;15:19-27. (Pubitemid 38139598)
39. Krug LM, Miller VA, Patel J, et al. Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma. Cancer 2005;104:2149-2155. (Pubitemid 41579961)
40. Cappuzzo F, Bemis L, Varella-Garcia M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med 2006;354:2619-2621. (Pubitemid 43882374)
41. Vallbohmer D, Brabender J, Yang DY, et al. Sex differences in the predictive power of the molecular prognostic factor HER2/neu in patients with non-small-cell lung cancer. Clin Lung Cancer 2006;7:332-337. (Pubitemid 43950981)
42. Raso MG, Behrens C, Herynk MH, et al. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res 2009; 15:5359-5368.
43. Agarwal M, Brahmanday G, Chmielewski GW, et al. Age, tumor size, type of surgery, and gender predict survival in early stage (stage I and II) non-small cell lung cancer after surgical resection. Lung Cancer 2010; 68:398-402.
44. Sekine I, Sumi M, Ito Y, et al. Gender difference in treatment outcomes in patients with stage III non-small cell lung cancer receiving concurrent chemoradiotherapy. Jpn J Clin Oncol 2009;39:707-712.
45. Videtic GM, Reddy CA, Chao ST, et al. Gender, race, and survival: a study in non-small-cell lung cancer brain metastases patients utilizing the radiation therapy oncology group recursive partitioning analysis classification. Int J Radiat Oncol Biol Phys 2009;75:1141-1147.
46. Cutolo M, Sulli A, Craviotto C, et al. Modulation of cell growth and apoptosis by sex hormones in cultured monocytic THP-1 cells. Ann N Y Acad Sci 2002;966:204-210. (Pubitemid 34729175)
47. Lee ML, Chen GG, Vlantis AC, et al. Induction of thyroid papillary carcinoma cell proliferation by estrogen is associated with an altered expression of Bcl-xL. Cancer J 2005;11:113-121.
48. Schmitt M, Klinga K, Schnarr B, et al. Dehydroepiandrosterone stimulates proliferation and gene expression in MCF-7 cells after conversion to estradiol. Mol Cell Endocrinol 2001;173:1-13. (Pubitemid 32149627)
49. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000;18:3651-3664.
50. S. Paik, Kim C, Jeong J, et al. Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3- and/or FISH-positive tumors: central testing results from NSABP B-31 (Abstract). ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2007;25, No 18S:511.
51. Clamon G, Herndon J, Kern J, et al. Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2:39810: a phase II trial of Cancer and Leukemia Group B. Cancer 2005;103:1670-1675. (Pubitemid 40490028)